Please assess the completion status of the following clinical trial:

Trial Title: Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Male or female Chinese patient with idiopathic Parkinson's disease (PD) confirmed by at least two of the following signs: resting tremor, bradykinesia, rigidity.~2. Parkinson's disease diagnosed for at least 2 years.~3. Patients 30 years of age or older at the time of diagnosis.~4. Modified Hoehn and Yahr stage of 2 to 4 at on-time.~5. If a patient is treated with standard or controlled release Levodopa combined with a Dopa-Decarboxylase-inhibitor or with Levodopa combined with a Dopa-Decarboxylase-inhibitor/entacapone, the dosage should be optimised according to investigator's judgement, and stable for at least 4 weeks prior to baseline visit.~6. If a patient treated with Levodopa combined with a Dopa-Decarboxylase-inhibitor has motor fluctuations, he should not have more than 6 hours of off-time every day during waking hours (documented on a patient diary completed for 2 consecutive days before baseline visit).~7. Patient willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures (in particular, after training, the patient should be able to recognise the off-time and on-time periods during waking hours and to record them accurately in the patient diary).~8. Signed informed consent obtained before any study procedures are carried out (in accordance with International Conference on Harmonisation-Good Clinical Practice guidelines and local legislation).~Exclusion criteria:~Medical exclusions:~1. Atypical parkinsonian syndromes due to drugs (e.g., metoclopramide, flunarizine), metabolic disorders (e.g., Wilson's disease), encephalitis or degenerative diseases (e.g., progressive supranuclear palsy).~2. Dementia, as defined by a Mini-Mental State Exam score \< 24 at screening visit \[R96-2656\].~3. Any psychiatric disorder according to Diagnostic and Statistical Manual of Mental Disorders (4th edition)criteria that could prevent compliance or completion of the study and/or put the patient at risk if he/she takes part in the study.~4. History of psychosis, except history of drug induced hallucinations (provided the investigator considers that participation to the trial would not represent a significant risk for the patient).~5. History of deep brain stimulation~6. Clinically significant electrocardiogram abnormalities at screening visit, according to investigator's judgement.~7. Clinically significant hypotension (i.e. supine systolic blood pressure \< 90 mmHg) and/or symptomatic orthostatic hypotension (i.e. clinical symptoms of orthostatic hypotension associated with a decline \>=20 mmHg in systolic blood pressure and a decline \>= 10 mmHg in diastolic blood pressure, at one minute after standing compared with the previous supine systolic and diastolic blood pressure obtained after 5 minutes of quiet rest) at screening or baseline visit.~8. Malignant melanoma or history of previously treated malignant melanoma.~9. Any other clinically significant disease, whether treated or not, that could put the patient at risk or could prevent compliance or completion of the study.~10. Pregnancy (to be excluded by urine pregnancy test at screening visit) or breast-feeding.~11. Sexually active female of childbearing potential (less than 6 months post-menopausal and not surgically sterilised) not using a medically approved method of birth control (i.e. oral contraceptives, intrauterine device, or double-barrier) for at least one month prior to the screening visit and throughout the study period (up to the follow-up visit).~12. Serum levels of Aspartate Aminotransferase, Alanine Aminotransferase , alkaline phosphatases or total bilirubin \> 2 Upper Limit of Normal (on screening lab test).~13. Patients with a creatinine clearance \< 50 mL/min/1.73m2 (estimated by the local lab / the investigator using the Modification of Diet in Renal Disease (MDRD), and calculated on screening lab test)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- pramipexole Extended release (Type: EXPERIMENTAL): subjects will receive 0.375mg once a day to 4.5mg once a day depending on investigator's judgement
- pramipexole Immediate release (Type: ACTIVE_COMPARATOR): subjects will receive 0.125mg three times a day to 1.0mg three times a day depending on investigator's judgement

Based on this trial design, predict the completion outcome and termination type (if applicable).